Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants

Brazil currently has a 10-valent pneumococcal conjugate vaccine (PCV10) pediatric national immunization program (NIP). However, in recent years, there has been significant progressive increases in pneumococcal disease attributed to serotypes 3, 6A, and 19A, which are covered by the 13-valent PCV (PC...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Hum Vaccin Immunother
Autores principales: Perdrizet, Johnna, Santana, Carlos Felipe S., Senna, Thais, Alexandre, Rodrigo Fernandes, Sini de Almeida, Rodrigo, Spinardi, Julia, Wasserman, Matt
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2020
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018448/
https://ncbi.nlm.nih.gov/pubmed/32966176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2020.1809266
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares